PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Knight Therapeutics Inc. (GUD.TO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

CA4990531069

CUSIP

499053106

Sector

Healthcare

Highlights

Total Revenue (TTM)

CA$182.18M

Gross Profit (TTM)

CA$66.49M

EBITDA (TTM)

CA$32.90M

Year Range

CA$5.09 - CA$6.23

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of CA$10,000 in Knight Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%-5.00%0.00%5.00%10.00%15.00%SeptemberOctoberNovemberDecember2025February
-1.58%
14.34%
GUD.TO (Knight Therapeutics Inc.)
Benchmark (^GSPC)

Returns By Period

Knight Therapeutics Inc. had a return of 5.24% year-to-date (YTD) and 3.88% in the last 12 months. Over the past 10 years, Knight Therapeutics Inc. had an annualized return of -4.93%, while the S&P 500 had an annualized return of 11.26%, indicating that Knight Therapeutics Inc. did not perform as well as the benchmark.


GUD.TO

YTD

5.24%

1M

0.90%

6M

-1.58%

1Y

3.88%

5Y*

-5.43%

10Y*

-4.93%

^GSPC (Benchmark)

YTD

4.01%

1M

1.13%

6M

9.82%

1Y

22.80%

5Y*

12.93%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of GUD.TO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20253.75%5.24%
20242.31%2.45%-2.57%8.87%3.99%-5.50%0.88%-4.02%8.01%-4.89%-6.56%1.33%2.89%
2023-1.16%-0.39%-13.73%2.27%6.67%2.92%-2.23%-5.38%-1.53%1.11%13.19%0.78%0.19%
20224.72%-1.98%-4.04%2.11%2.44%-2.20%8.43%-1.55%-6.84%4.52%-2.70%-4.07%-2.26%
2021-1.12%-2.46%5.23%-0.55%-1.67%-1.13%-2.48%4.88%-0.37%-3.93%2.53%0.57%-0.93%
20203.56%-15.03%-7.05%22.42%0.26%-7.75%-1.42%-10.26%-6.60%-5.69%0.73%-2.90%-29.42%
20192.47%-2.92%-4.05%-0.54%3.29%2.39%-2.98%0.53%-1.33%12.79%-6.92%-2.82%-1.43%
2018-8.54%1.97%-0.00%1.42%2.29%0.12%6.21%1.05%-4.86%-4.38%8.78%-10.06%-7.46%
2017-4.28%4.28%-3.08%2.12%-5.56%2.69%-7.77%-10.64%2.00%-3.12%-7.16%6.81%-22.63%
2016-12.31%10.49%5.61%2.41%2.97%-0.36%2.29%3.18%8.22%-5.91%15.81%3.97%39.12%
201517.20%12.95%-10.70%-9.54%-10.41%1.06%11.19%-5.37%0.14%10.34%-0.13%-0.77%11.56%
201437.86%10.04%-2.75%-4.42%-5.00%6.63%12.25%-5.21%17.35%1.32%80.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GUD.TO is 48, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GUD.TO is 4848
Overall Rank
The Sharpe Ratio Rank of GUD.TO is 5252
Sharpe Ratio Rank
The Sortino Ratio Rank of GUD.TO is 4343
Sortino Ratio Rank
The Omega Ratio Rank of GUD.TO is 4242
Omega Ratio Rank
The Calmar Ratio Rank of GUD.TO is 5050
Calmar Ratio Rank
The Martin Ratio Rank of GUD.TO is 5353
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Knight Therapeutics Inc. (GUD.TO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for GUD.TO, currently valued at 0.16, compared to the broader market-2.000.002.000.161.74
The chart of Sortino ratio for GUD.TO, currently valued at 0.40, compared to the broader market-4.00-2.000.002.004.006.000.402.36
The chart of Omega ratio for GUD.TO, currently valued at 1.05, compared to the broader market0.501.001.502.001.051.32
The chart of Calmar ratio for GUD.TO, currently valued at 0.08, compared to the broader market0.002.004.006.000.082.62
The chart of Martin ratio for GUD.TO, currently valued at 0.46, compared to the broader market-10.000.0010.0020.0030.000.4610.69
GUD.TO
^GSPC

The current Knight Therapeutics Inc. Sharpe ratio is 0.16. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Knight Therapeutics Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
0.16
2.32
GUD.TO (Knight Therapeutics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Knight Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-48.44%
-1.46%
GUD.TO (Knight Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Knight Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Knight Therapeutics Inc. was 60.09%, occurring on Mar 27, 2023. The portfolio has not yet recovered.

The current Knight Therapeutics Inc. drawdown is 48.44%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-60.09%Feb 23, 20171528Mar 27, 2023
-38.07%Feb 26, 2015240Feb 9, 2016194Nov 16, 2016434
-29.77%Apr 11, 201467Jul 17, 201496Dec 3, 2014163
-11.89%Mar 21, 20145Mar 27, 20144Apr 2, 20149
-8.57%Dec 6, 20165Dec 12, 201642Feb 13, 201747

Volatility

Volatility Chart

The current Knight Therapeutics Inc. volatility is 6.47%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%SeptemberOctoberNovemberDecember2025February
6.47%
3.39%
GUD.TO (Knight Therapeutics Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Knight Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Knight Therapeutics Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab